Abstract:Human immunodeficiency virus type 1 (HIV-1) is a major global health problem, with over 38 million people infected worldwide. Current anti-HIV-1 drugs are limited in their ability to prevent the virus from replicating inside host cells, making them less effective as preventive measures. In contrast, viral inhibitors that inactivate the virus before it can bind to a host cell have great potential as drugs. In this study, we aimed to design mutant peptides that could block the interaction between gp120 and the CD4 receptor on host cells, thus preventing HIV-1 infection. We designed a 20-amino-acid peptide that mimicked the amino acids of the CD4 binding site and docked it to gp120. Molecular dynamics simulations were performed to calculate the energy of MMPBSA (Poisson-Boltzmann Surface Area) for each residue of the peptide, and unfavorable energy residues were identified as potential mutation points. Using MAESTRO (Multi AgEnt STability pRedictiOn), we measured ΔΔG (change in the change in Gibbs free energy) for mutations and generated a library of 240 mutated peptides using OSPREY software. The peptides were then screened for allergenicity and binding affinity. Finally, molecular dynamics simulations (via GROMACS 2020.2) and control docking (via HADDOCK 2.4) were used to evaluate the ability of four selected peptides to inhibit HIV-1 infection. Three peptides, P3 (AHRQIRQWFLTRGPNRSLWQ), P4 (VHRQIRQWFLTRGPNRSLWQ), and P9 (AHRQIRQMFLTRGPNRSLWQ), showed practical and potential as HIV inhibitors, based on their binding affinity and ability to inhibit infection. These peptides have the ability to inactivate the virus before it can bind to a host cell, thus representing a promising approach to HIV-1 prevention. Our findings suggest that mutant peptides designed to block the interaction between gp120 and the CD4 receptor have potential as HIV-1 inhibitors. These peptides could be used as preventive measures against HIV-1 transmission, and further research is needed to evaluate their safety and efficacy in clinical settings.

Low-molecular-weight anti-HIV-1 agents targeting HIV-1 capsid proteins

Cyclic Peptide Inhibitors of HIV-1 Capsid-Human Lysyl-Trna Synthetase Interaction.

Potent leads based on CA-19L, an anti-HIV active HIV-1 capsid fragment

Design, synthesis, and antiviral activity of phenylalanine derivatives as HIV-1 capsid inhibitors

Antiviral Inhibition Of The Hiv-1 Capsid Protein

Discovery of low‐molecular‐weight phenylalanine derivatives as novel HIV capsid modulators with improved antiretroviral activity and metabolic stability

Exploratory studies on CA-15L, an anti-HIV active HIV-1 capsid fragment

Modulation of HIV-1 capsid multimerization by sennoside A and sennoside B via interaction with the NTD/CTD interface in capsid hexamer

Dual targeting inhibitors for HIV-1 capsid and cyclophilin A: molecular docking, molecular dynamics, and quantum mechanics

Small-Molecule CD4 Mimics Containing Mono-cyclohexyl Moieties as HIV Entry Inhibitors

Anti-virus reagents targeting the capsid protein assembly

Quinazolinone-based subchemotypes for targeting HIV-1 capsid protein: design and synthesis

A new class of capsid-targeting inhibitors that specifically block HIV-1 nuclear import

Discovery and Mechanistic Investigation of Piperazinone Phenylalanine Derivatives with Terminal Indole or Benzene Ring as Novel HIV-1 Capsid Modulators

A “Two-Birds-One-Stone” Approach toward the Design of Bifunctional Human Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5 Coreceptor and gp41 N-Terminal Heptad Repeat Region

Small organic molecules targeting PCAF bromodomain as potent inhibitors of HIV-1 replication

Structure of the Antiviral Assembly Inhibitor CAP-1 Complex with the HIV-1 CA Protein

Design, Synthesis, and Biological Evaluation of Highly Potent Small Molecule–Peptide Conjugates As New HIV-1 Fusion Inhibitors

Inactivation of cell-free HIV-1 by designing potent peptides based on mutations in the CD4 binding site

Modular HIV-1 Capsid Assemblies Reveal Diverse Host-Capsid Recognition Mechanisms

Flexibility of small molecular CD4 mimics as HIV entry inhibitors